Literature DB >> 2474678

Mutational analysis of the human immunodeficiency virus vpr open reading frame.

K Ogawa1, R Shibata, T Kiyomasu, I Higuchi, Y Kishida, A Ishimoto, A Adachi.   

Abstract

Mutations were introduced by recombinant DNA techniques into the vpr open reading frame of an infectious molecular clone of human immunodeficiency virus type 1. The effect of these changes on the replicative and cytopathologic properties of the virus recovered from transfected cells was studied in several human CD4+ lymphocyte cell lines. In all cases, mutant viruses were infectious and cytopathic. However, when a low-input dose was used, mutants grew significantly more slowly than the wild-type virus. The growth kinetics of vpr mutants were distinct from those of vif and vpu mutants.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2474678      PMCID: PMC251018     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  36 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Nucleotide sequence and expression of an AIDS-associated retrovirus (ARV-2).

Authors:  R Sanchez-Pescador; M D Power; P J Barr; K S Steimer; M M Stempien; S L Brown-Shimer; W W Gee; A Renard; A Randolph; J A Levy
Journal:  Science       Date:  1985-02-01       Impact factor: 47.728

3.  Nucleotide sequence of the AIDS virus, LAV.

Authors:  S Wain-Hobson; P Sonigo; O Danos; S Cole; M Alizon
Journal:  Cell       Date:  1985-01       Impact factor: 41.582

4.  Nucleic acid structure and expression of the human AIDS/lymphadenopathy retrovirus.

Authors:  M A Muesing; D H Smith; C D Cabradilla; C V Benton; L A Lasky; D J Capon
Journal:  Nature       Date:  1985 Feb 7-13       Impact factor: 49.962

5.  HTLV-III infection in brains of children and adults with AIDS encephalopathy.

Authors:  G M Shaw; M E Harper; B H Hahn; L G Epstein; D C Gajdusek; R W Price; B A Navia; C K Petito; C J O'Hara; J E Groopman
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

6.  Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR.

Authors:  N Ahmad; S Venkatesan
Journal:  Science       Date:  1988-09-16       Impact factor: 47.728

7.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

9.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

10.  Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS.

Authors:  J A Levy; A D Hoffman; S M Kramer; J A Landis; J M Shimabukuro; L S Oshiro
Journal:  Science       Date:  1984-08-24       Impact factor: 47.728

View more
  81 in total

1.  Impairment of human immunodeficiency virus type 1 (HIV-1) entry into Jurkat T cells by constitutive expression of the HIV-1 vpr protein: role of CD4 down-modulation.

Authors:  L Conti; B Varano; M C Gauzzi; P Matarrese; M Federico; W Malorni; F Belardelli; S Gessani
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

2.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

Review 3.  Mechanism of action of regulatory proteins encoded by complex retroviruses.

Authors:  B R Cullen
Journal:  Microbiol Rev       Date:  1992-09

4.  Dual regulation of silent and productive infection in monocytes by distinct human immunodeficiency virus type 1 determinants.

Authors:  P Westervelt; T Henkel; D B Trowbridge; J Orenstein; J Heuser; H E Gendelman; L Ratner
Journal:  J Virol       Date:  1992-06       Impact factor: 5.103

5.  Generation of a chimeric human and simian immunodeficiency virus infectious to monkey peripheral blood mononuclear cells.

Authors:  R Shibata; M Kawamura; H Sakai; M Hayami; A Ishimoto; A Adachi
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 Vpr arrests the cell cycle in G2 by inhibiting the activation of p34cdc2-cyclin B.

Authors:  F Re; D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  Regulatory genes of simian immunodeficiency viruses from west African green monkeys (Cercopithecus aethiops sabaeus).

Authors:  V Jubier-Maurin; P Sarni-Manchado; F Veas; N Vidal; F Bibollet-Ruche; J P Durand; A Galat-Luong; G Cuny
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

9.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

10.  A domain of human immunodeficiency virus type 1 Vpr containing repeated H(S/F)RIG amino acid motifs causes cell growth arrest and structural defects.

Authors:  I G Macreadie; L A Castelli; D R Hewish; A Kirkpatrick; A C Ward; A A Azad
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.